July 2015

Author:
Tim Mitchell, Vice President, Strategic Partnerships & MRO
Roy Martin, Vice President, Preclinical Services
Ann Quinlan-Smith, Division President, Clinical and Consulting NAMSA

Abstract:

When a medical device company uses NAMSA for both preclinical and clinical programs, as much as 6 months can be cut from the product development timeline. For the average 510(k) device with a 60-month development cycle, that could equate to a 10% reduction in total development time. For a product with annual revenues of $100 million, that can translate to a gain of $50 million in revenue. For smaller companies and start-ups, that means 6 months less cash burn before revenue starts to flow.